SLC5A2 and type 2 diabetes mellitus: It has been reported that SGLT2 inhibitors maintain motivation for treatment and increase treatment satisfaction in patients with T2DM (39), while improvements in the plasma glucose profile also improve well-being in T2DM patients with hyperglycemia or insulin resistance (40).